Home LiteratureArticle Details
PMID: 10960464 Published · ppublish English Clinical Trial Journal Article

Standardization of hepatitis C virus RNA quantification.

Hepatology (Baltimore, Md.) ·Vol. 32 ·No. 3 ·2000-09-00 ·Pages 654-9

Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D

Abstract

It was recently recommended that hepatitis C virus (HCV) RNA quantification be used to tailor the duration of combined interferon alfa (IFN-alpha)/ribavirin therapy in patients infected by HCV genotypes 1, 4, and 5. This recommendation has been difficult to implement in the absence of standardized quantitative units for HCV RNA. The aim of this work was to define clinically relevant HCV RNA loads in standardized international units (IU), for use in routine clinical and research applications based on standardized quantitative assays. Two hepatitis C virus RNA quantitative assays were used: (1) the Superquant assay (National Genetics Institute, Los Angeles, CA), for which possibly relevant thresholds were established; and (2) the semi-automated Cobas Amplicor HCV Monitor assay version 2.0 (Cobas v2.0, Roche Molecular Systems, Pleasanton, CA) that measures HCV RNA loads in IU/mL. Quantification in the Cobas v2.0 assay was linear over the entire range of values tested, including viral loads higher than 850,000 IU/mL after 100-fold dilution. The accuracy and precision of the measures in IU/mL were satisfactory with Cobas v2.0. The results obtained with Superquant and Cobas v2.0 correlated (r =.932; P <.0001). A value of 2,000,000 copies/mL (6.3 log(10) copies/mL) with Superquant was converted to nearly 800,000 IU/mL (5.9 log(10) IU/mL). In conclusion, all HCV RNA quantitative assays should give HCV RNA loads in international units and be validated with appropriate calibrated panels; 800,000 IU/mL in any of these assays should be used as the decision threshold to tailor the IFN-alpha/ribavirin treatment duration in patients infected by HCV genotypes 1, 4, and 5.

MeSH Terms
Antiviral Agents/therapeutic use Drug Therapy, Combination Genetic Techniques/standards Hepacivirus/genetics Hepatitis C/drug therapy,genetics,virology Humans Interferon-alpha/therapeutic use RNA, Viral/analysis Reference Standards Ribavirin/therapeutic use
Chemicals
Antiviral Agents Interferon-alpha RNA, Viral Ribavirin
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Pawlotsky J M
Department of Bacteriology and Virology, Hôpital Henri Mondor, Université Paris XII, Créteil, France. jean-michel.pawlotsky@hmn.ap-hop-paris.fr
Bouvier-Alias M
Hezode C
Darthuy F
Remire J
Dhumeaux D
Article Info
Journal
Hepatology (Baltimore, Md.)
Abbr.
Hepatology
ISSN
0270-9139
Published
2000-09-00
Pages
654-9
Language
English
Region
United States
NLM ID
8302946
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com